In the second installment of Oppenheimer's ‘Following the Cash' report, “we check in on the balance sheet and cash flow generation of the large cap medical device group through year-end 2010.”
“As we looked through the 4Q comments of the major medical device companies, cash was indeed a theme,” Oppenheimer writes. “Market growth remains challenged, and investors continue to press managements on how cash will be deployed.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
“Acquisition activity has picked up over the past year, but there is balance sheet room for more. We believe Outperform-rated Medtech's (NYSE: MDT) cash flow generation remains underappreciated. The company leads traditional Medtech in free cash flow yield and dividend yield, and is among the leaders in share buybacks.”
Medtech closed Friday at $38.08.